PureTech Health PLC

PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries’ Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.

Karuna Therapeutics Inc

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological condit

PureTech Founded Entity Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia

AIM ImmunoTech Inc

Avid Bioservices

CytoDyn Inc.

Fulgent Genetics

Humanigen

Jaguar Health

Keep in mind downside risk, if their respective candidates fail to pan out. But, there may be opportunity with these seven biotech stocks targeting treatments for long-haul Covid-19.

7 Biotech Stocks Focused on Chronic Covid Treatment

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vor Biopharma Closes Over $200M Initial Public Offering

PureTech Founded Entity Vor Biopharma Closes Over $200M Initial Public Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta announces $25 million investment from Pfizer Inc. as part of the Pfizer Breakthrough Growth Initiative.

Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta announces $25 million investment from Pfizer Inc. as part of the Pfizer Breakthrough Growth Initiative.

PureTech Founded Entity Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.

BOSTON--(BUSINESS WIRE)--PureTech (Nasdaq: PRTC) initiated a global, Phase 2 trial of LYT-100 (deupirfenidone) in Long COVID respiratory complications and related sequelae.

PureTech Initiates Phase 2 trial of LYT-100 (Deupirfenidone) in Long COVID Respiratory Complications and Related Sequelae

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors

PureTech Founded Entity Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors

News for PureTech Health PLC Stock (PRTC)